Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

Glenmark Specialty S.A. and Lotus International Pte. Ltd. enter into Exclusive Licensing Agreement for commercializing Ryaltris (TM) Nasal Spray in Singapore, Hong Kong and Vietnam

* Under the terms of the agreement, Glenmark will be responsible for the manufacture and supply of Ryaltris™, while Lotus International Pte. Ltd. will be responsible for the commercialization of Ryaltris™ (subject to receipt of regulatory approvals) across these markets. * Glenmark will recei...

2022-01-20 15:48 3342

Nippon Express (Belgium) Acquires GDP Certification for Facility in Brussels Airport's Cargo Area

TOKYO, Jan. 20, 2022 /PRNewswire/ -- Nippon Express (Belgium) N.V./S.A. (hereinafter "NX Belgium"), a company of the Nippon Express Holdings, Inc. Group, has obtained Good Distribution Practice (GDP) certification, effective December 21, 2021, for air and ground forwarding operations, inclusive of...

2022-01-20 15:00 2206

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the fourth consecutive year for the certification inThailand * High scores in values, ethics and integrity serve as a driver for a strong c...

2022-01-20 08:00 3232

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the third consecutive year for the certification inIndonesia * High scores in values, ethics and integrity serve as a driver for a strong c...

2022-01-20 08:00 3560

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the fourth consecutive year for the certification inPhilippines * High scores in values, ethics and integrity serve as a driver for a strong...

2022-01-20 08:00 2951

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the second consecutive year for the certification inAustralia & New Zealand * High scores in values, ethics and integrity serve as a driver ...

2022-01-20 08:00 2862

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the fourth consecutive year for the certification inMalaysia * High scores in values, ethics and integrity serve as a driver for a strong c...

2022-01-20 08:00 2891

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the fifth consecutive year for the certification inSingapore * High scores in values, ethics and integrity serve as a driver for a strong c...

2022-01-20 08:00 2594

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the third consecutive year for the certification inVietnam * High scores in values, ethics and integrity serve as a driver for a strong cor...

2022-01-20 08:00 6462

"JEWISH NOBEL" AWARDED TO PFIZER CEO ALBERT BOURLA

Genesis Prize Chairman highlights immense role of Jewish scientists and doctors in combatting the pandemic: "A very proud moment for the entire Jewish community" JERUSALEM, Jan. 20, 2022 /PRNewswire/ -- Today, The Genesis Prize Foundation announced Dr.Albert Bourla, Chairman and CEO of Pfizer,...

2022-01-20 06:13 2516

Neurophth Therapeutics Receives IND Clearance to Initiate Clinical Trial for China AAV-ND4 Gene Therapy NR082 in Leber Hereditary Optic Neuropathy

WUHAN, China and SAN DIEGO, Jan. 19, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth"), today announced receiving the U.S. Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application on thein-vivo gene replacement thera...

2022-01-19 22:30 2430

Qilian International Holding Group Limited Receives Approval for the Sale of its Newly Developed Nitrofurantoin Enteric-coated Tablets

JIUQUAN, China, Jan. 19, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), aChina-based pharmaceutical and chemical products manufacturer, today announced that the Company received approval from Gansu Provin...

2022-01-19 20:30 2353

Seegene to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing

SEOUL, South Korea, Jan. 19, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced today the upcoming launch of the Allplex™ SARS-CoV-2 Fast PCR Assay, which can deliver PCR results in just 60 minutes. The company says that this assay is exp...

2022-01-19 20:00 2669

Seegene to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing

Accomplished Pharma R&D leader, Sauri Gudlavalleti joins Sai Life Sciences as Chief Operating Officer

HYDERABAD, India, Jan. 19, 2022 /PRNewswire/ -- Sai Life Sciences, a leading globalContract Research, Development & Manufacturing Organization (CRO-CDMO), today announced the app...

2022-01-19 18:30 4331

Accomplished Pharma R&D leader, Sauri Gudlavalleti joins Sai Life Sciences as Chief Operating Officer

XtalPi Partners with Excelra for GOSTAR to Enhance its Intelligent Digital Drug Discovery and Development platform

HYDERABAD, India and SHENZHEN, China, Jan. 19, 2022 /PRNewswire/ -- Excelra, a leading global Data & Analytics organization, today announced the partnership for its Global Online Structure Activity Relationship Database (GOSTAR) with XtalPi Inc., an AI-based pharmaceutical biotechnology company r...

2022-01-19 09:00 9989

ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data

SHENZHEN, China, Jan. 18, 2022 /PRNewswire/ -- ImmVira's breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has recently completed first 2 cohorts dose-escalation of U.S. Phase I clinical study, and demonstrated good saf...

2022-01-19 08:30 2058

ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data

CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients

* Sugemalimab is the world's first PD-L1 monoclonal antibody that when administered along with chemotherapy improved overall survival of first-line metastatic squamous and non-squamous non-small cell lung cancer patients in a statistically significant and clinically meaningful manner * Surviv...

2022-01-19 08:05 4336

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis

HANGZHOU, China, Jan. 19, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced today that the first patient has been dosed with LNK01001 in its Phase II clinical trial targeting ankylosing spondyli...

2022-01-19 08:00 4186

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors

SHANGHAI and GAITHERSBURG, Md., Jan. 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in itsChina phase ...

2022-01-18 21:00 2200

CN Energy Signs Operation & Management Agreement; Enters Multi-Billion Dollar Pharmaceutical Excipients Market

LISHUI, China, Jan. 18, 2022 /PRNewswire/ -- CN Energy Group. Inc. (the "Company") today announced that its subsidiary Hangzhou Forasen Technology Co., Ltd. signed an operation and management ("O&M") agreement (the "Agreement") with HuaiNan JiaHe New Materials Co., Ltd. ("JiaHe") and JiaHe's acti...

2022-01-18 21:00 2411

1 ... 306 307 308309310 311 312 ... 344